• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Healthcare·LLY
Share

Eli Lilly and Company Stocks

$ 1136.37Last Updated 10.06.2026

Issuer Rating

6/7
Performance

Favourable

Risk

Low

Recommendation

Buy

Market Cap

$ 1.08T

$ 1136.37
Key Takeaways

Risk factor

Negligible price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Excellent growth

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Latest news

09.06.2026 16:00

Morning in New York: news contributes to moderate positivity

08.06.2026 18:30

'Eli Lilly pulls ahead': investors praise new obesity drug

05.06.2026 13:17

Defeating dementia: where Eli Lilly is investing $4 billion

30.05.2026 13:01

Highlights of the week: Anthropic record, new "trillionaires", Blue Origin failure

26.05.2026 19:58

Eli Lilly will invest nearly $4 billion to buy three vaccine developers. Why would she do that?

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Company Valuation

Greatly overvalued
1/7

Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EB

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of LLY is 1192 and suggests 4% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendation su

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

11.06.2026 18:17

Trump has vowed to launch more strikes against Iran. Iran threatened to attack Musk's companies

11.06.2026 17:45

Italy's SJI promoted "Superjets" abroad. How does it survive under sanctions?

11.06.2026 17:26

ECB raises rate for first time since 2023

11.06.2026 17:00

IPO hopes and dreams: why iconic shortstop Jim Chanos doesn't believe SpaceX's valuation

11.06.2026 16:35

FDA decisions and clinical data: the main drivers in small-cap biotech through the end of June

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn
  • X (Twitter)
  • LinkedIn
Oninvest© 2026